Fasciitis, Necrotizing Clinical Trial
Official title:
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.
Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have already demonstrated that daptomycin was noninferior to the comparator agent (vancomycin or beta-lactams) (10). Although this clinical trial did not include any patients with clostridial infection, there is in vitro data to support the activity of daptomycin against a variety of clostridial species(11) ( Clostridium perfringens) Therefore, for this trial we will include patients with clostridial infections with this species. Additionally, the patients in the SSTI study were not as ill as the proposed study population. Therefore for treatment of such severe infections, we would like to use a higher dose of daptomycin (6mg/kg/dose). The reasons for using a higher dose of daptomycin in this subgroup are as follows: 1. Patients who are severely ill have an increased volume of distribution; and therefore have a lower serum concentration of daptomycin. These patients might require a higher dose of daptomycin to achieve the desired serum concentration. 2. One of the organisms involved in necrotizing fasciitis is enterococcus (both-fecalis and faecium). E.faecium has higher MICs to daptomycin and would require a higher dose of the drug to achieve adequate free (unbound) serum concentration of the drug. 3. Both necrotizing fasciitis and endocarditis are serious deep seated infections. The clinical trials for endocarditis are using 6mg/kg/dose of daptomycin. Therefore for optimal treatment of necrotizing fasciitis, it is justifiable that we should use the higher dose of daptomycin. Objective: To evaluate the clinical and microbiological efficacy and safety of higher dose daptomycin therapy in the treatment of patients with severe necrotizing skin and soft tissue infections. Type of Study: Open label, single center study.
At the shock trauma center, the management of patients with NSTI is conducted in the following fashion: All new patients with NSTI are admitted to the trauma center through the 12-bed shock trauma admitting area. Full hemodynamic resuscitation is undertaken. The on-call soft-tissue and infection team is mobilized. Standard investigations, radiographic evaluations, and laboratory tests, including gram stain and culture specimens, are obtained. The University of Maryland Medical Systems/shock trauma laboratory is utilized for hematology, biochemical, and bacteriologic studies. Aggressive empiric broad-spectrum antibiotic therapy is instituted. The standard antibiotic therapy for NSTI's at shock trauma includes the following: Gram negative rods: Piperacillin/Tazobactam or quinolones or aztreonam / + aminoglycosides Anaerobes: Piperacillin/Tazobactam or Metronidazole or Clindamycin Gram positive cocci (not MRSA/VRE): Piperacillin/Tazobactam or Clindamycin Gram positive cocci (MRSA): Vancomycin Gram positive cocci (VRE): Linezolid For purposes of this study, daptomycin would replace Vancomycin, Linezolid or clindamycin for gram positive coverage. Prior antibiotic therapy, culture data, comorbid conditions, allergy history and other variables may result in institution of a different antibiotic regimen. The patient is taken to the shock trauma operating room for debulking of infected tissue (excision and debridement) and reculturing. Postoperatively, the patient is moved to a critical or intensive care unit for further management and monitoring. When the patient is stable, HBO is begun within 12 hours of arrival. Once the patient is enrolled in the study the following procedures will be followed: Antibiotic Therapy: Once the patient is consented, the antibiotic therapy will be started. The combination regimen will include the following drugs in standard approved dosing. - Gram negative bacteria: Aztreonam or ciprofloxacin / + aminoglycosides* - Anaerobic bacteria: Metronidzole - Gram positive bacteria: Daptomycin For all patients the recommended dose of Daptomycin will be 6 mgm/kg/day administered over 30 minutes. A pharmacokinetic study performed in obese patients demonstrated that daptomycin could be dosed based on total body weight. No adjustment in daptomycin dose should be required based solely on obesity (12). Any patient who develops a decrease in renal function during the study to the point where his/her creatinine clearance (CrCl) falls below 30 mL/min would have their dose adjusted to 6 mg/kg every 48 hours, the interval recommended by the package insert. This includes patients who go on to require conventional hemodialysis. Since there are no data available on the pharmacokinetics (PK) of daptomycin in patients receiving continuous renal replacement therapy (CRRT), and therefore no recommendation for dosage adjustment, these patients would be removed from the study and initiated on a standard of care regimen . Treatment duration will be 7-14 days. - Aminoglycosides will be added if there is suspicion or documentation of resistant gram negative rods. At various intervals, the following information will be collected or procedures will be followed: (See attached study schedule) Baseline 1. Demographic data - age, gender, weight, height, nursing home residence 2. Number and length of previous hospitalizations in last six months 3. Nature and duration of symptoms 4. Admission status including vital signs, GCS, APACHE, SIRS scores, CBC with diff, CPK, lactate, BUN, creatinine, liver function tests, blood gases if on ventilator, cultures of wound-aerobic and anaerobic. 5. Prior surgery for NSTI - number and dates 6. Comorbid conditions - diabetes, peripheral vascular disease, immunocompromised, etc. 7. Prior antibiotics over last six months - dose/route/type 8. Prior cultures of NSTI, presence of resistant bacteria. 9. Wound size - length, depth in cm. 10. Use of drugs such as HMG-CoA reductase inhibitors At various intervals, the following procedures will be followed:. - GCS, vital signs, CBC, CPK, BUN, creatinine, liver functions, blood gases if ventilated - Wound size in cm - Surgical intervention - Cultures of wound, (both aerobic and anaerobic), blood, super infections. Preferably cultures of the debrided tissue or purulent material will be obtained. If there is no tissue or pus available, only then a deep culture of the wound will be obtained. The culture will be evaluated in the microbiologic lab for gram stain, culture (aerobic and anaerobic if already indicated) and antimicrobiological sensitivity (by standard CLSI (NCCLS) techniques. The organisms in the study will be identified at the genus and species level. - LOS - hospital, ICU - Wound dressing - type - Use of vacuum assisted dressing - Duration of antibiotic therapy - Adverse events - Mortality - Patient will be evaluated clinically on a daily basis by several clinical services (surgery, infectious diseases, critical care, hyperbaric medicine)and safety labs will be obtained every 3-5days. If a patient is failing therapy then based on available microbiological determinants, patient will be changed to an appropriate antibiotic regimen. The End points of the study are as follows: - clinical cure at 7-14 days - clinical failure at any point after 72 hours of treatment - if the patient is clinically cured and there is persistence of initial infective organism in the wound culture, the study would be terminated. However, if the patient is worse then appropriate treatment will be initiated and study drug will be discontinued. - if the patient experiences a serious adverse event related to the study drug, the study drug will be terminated. - if the patient decides to withdraw consent. Clinical Response at the end of treatment (7-14 days) and test of cure (3-28 days) post end of treatment): - Cure: Resolution of clinically significant signs and symptoms* associated with the infected wound present at the time of study entry and no additional gram-positive antibiotic therapy is needed until the end of treatment visit. - Improved: Partial resolution of clinical signs and symptoms* of the wound (e.g., although the patient's clinical status has not completely returned to pre-infection baseline, the infectious process has been controlled) and no additional gram-positive antibiotic therapy is needed until the end of treatment visit. - Failure: No response or worsening of clinical signs and symptoms of infection; or new signs and symptoms of infection are present; or additional gram-positive antibiotic therapy is needed until the end of treatment visit. - Unable to Evaluate: Unable to determine response; e.g., no evaluation performed at the time point, or administration of non-study antibiotics effective against a study pathogen. * Clinically significant signs and symptoms are: - pain out of proportion to clinical findings - tenderness to palpation - elevated temps.[100.4] or reduced temps.[>96] - WBC counts > 12.000/cu.mm - swelling - erythema - induration - pus formation Microbiological Response at End of Treatment and Test of Cure Visit: - Documented Eradicated: The baseline infecting pathogen was absent at end of treatment as determined by a negative culture result. - Presumed Eradicated: The baseline infection was presumed absent at the end of treatment as determined that there was "nothing to culture". - Documented Persistent: The baseline infecting pathogen was present at the end of treatment. Patients will also be monitored for 3 - 28 days post therapy. Analysis Because of the small sample size (25 patients) stated above, this study will serve as a preliminary study to obtain data to evaluate the presence of positive trends in terms of outcome in the patients treated with Daptomycin. If favorable, this would warrant a larger prospective controlled study in which a larger sample size would allow for a more robust statistical analysis. Variables in the initial analysis will include antibiotic days, intensive care unit and hospital length of stay and mortality. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02469857 -
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
|
Phase 3 |